Centessa Pharmaceuticals (CNTA) Liabilities and Shareholders Equity (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $641.8 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $641.8 million, up 21.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 billion (up 7.4% YoY), and the FY2025 annual result was $687.5 million, up 19.19% from the prior year.
• Liabilities and Shareholders Equity slipped to $641.8 million in Q1 2026 per CNTA's latest filing, from $687.5 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $687.5 million in Q4 2025 and troughed at $328.2 million in Q1 2024.
• A 5-year average of $486.6 million and a median of $479.4 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity sank 30.63% in 2023, then soared 61.57% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $444.3 million in 2022, then decreased by 18.92% to $360.2 million in 2023, then soared by 60.11% to $576.8 million in 2024, then grew by 19.19% to $687.5 million in 2025, then slipped by 6.65% to $641.8 million in 2026.
• Business Quant data shows CNTA's Liabilities and Shareholders Equity at $641.8 million in Q1 2026, $687.5 million in Q4 2025, and $448.3 million in Q3 2025.